Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SARS and Avian Flu -- Ignore unavailable to you. Want to Upgrade?

To: Elroy Jetson who wrote (2718)	10/15/2005 1:48:17 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 4232

>> Not one viral IGG product that I'm aware of has ever led to an approved drug, in spite of decades of trials. << Purely an economic issue...... getting titers high enough from volunteers selected among random donors, and the expense of providing an intravenous product. The antibodies are there, and they've been shown to provide potent anti-viral protection in a variety of studies. >> You were misinformed when someone told you that monoclonal antibodies are not used to treat sepsis. << I didn't say that one can't find model systems and trials where MAbs have been effective. I said that you were wrong when you said that........ >> SEPSIS is now treated with man-made monoclonal antibodies to the antigen the immune system is responding to. << And I'm correct. Yes, you can provide GREAT protection with serotype-specific MAbs to a variety of Gram-negatives. One can't, however, make a cocktail that has any economic viability as a product. You are flat out wrong. TNF is not "the antigen the immune system is responding to", and E5 and HA-1A failed miserably, together with every other MAb that was purportedly specific for core endotoxin, in advanced testing. Miserably. A few links to crap preliminary studies from 1991 won't buy you much. A little basckground reading for you, Mr. Jetson..... pubmedcentral.gov

To: Elroy Jetson who wrote (2718)	10/15/2005 11:41:31 PM
From: Maurice Winn	Read Replies (2) \| Respond to of 4232

Elroy, let's suppose 2 out of 3 people survive humanized H5N1. That would mean there would be a huge amount of survivor blood juice [if they were offered a lot of money for their blood]: <Are you actually suggesting "preventative" injections of IGG for the world's population from the hundred or so bird flu survivors?> It might be a much better solution than goofing around with Tamiflu and Relenza which might or might not be useful - they won't even be available if a pandemic starts due to lack of production capacity. A blood extraction business could be started now, as Richard says, extracting blood from survivors and injecting it into people treating new victims to protect them. As more and more people experience the disease, there will be more and more blood available and more and more protected health workers. Each person who experiences the disease can go on producing blood, month after month, so the total volume of blood juice would become huge and general treatment would be available for those who were will to pay the price. It seems to me as though Richard has come up with an excellent idea. It's time to start the business. Where's the list of the names of cured victims? How much do they want for each 500 ml of blood we take from them? Who wants to buy immunity? We can probably store the stuff in big refrigerators until the price rises. Mqurice